Pharmaceutical Preparations · Z4 · CIK 1374339
Develops antibody therapies targeting toxic misfolded proteins for neurodegenerative diseases
Comparable business profile · signals at a glance
In the 90 days to Mar 5, 2026: 3 insiders bought $8.7M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 5, 2026 | Williams EugeneDirector | Buy | 2,000 | $24.40 | $49K |
| Mar 4, 2026 | Williams EugeneDirector | Buy | 2,000 | $24.00 | $48K |
| Mar 3, 2026 | Williams EugeneDirector | Buy | 1,000 | $21.89 | $22K |
| Mar 2, 2026 | Williams EugeneDirector | Buy | 1,000 | $22.53 | $23K |
| Feb 19, 2026 | Kaplan JohanneChief Development Officer | Buy | 1,629 | $15.35 | $25K |
| Feb 3, 2026 | Yu FanTenPercentOwner | Buy | 700,741 | $12.13 | $8.5M |
| Oct 3, 2025 | Milbury Max A.Other | Buy | 30,392 | $0.49 | $15K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.